L’enseignement des soins infirmiers se fait sous la tutelle du ministère de la Santé et de la Prévention médicale.Il est en pleine effervescence,mais seulement avec deux niveaux de formation.
- En premier lieu,il y a la formation initiale qu’une seule institution nationale a assurée de 195...2 à 1992.Avec la pénurie de la main-d’œuvre et la libéralisation de l’éducation,le Sénégal fait face depuis une quinzaine d’années à l’ouverture effrénée d’écoles privées dont la majorité dispose d’un agrément du ministère de la Santé.Le diplôme requis à l’entrée dans ces institutions de formation est le baccalauréat de l’enseignement général (13 ans de scolarité).La durée des études est de trois années sanctionnées par un diplôme d’État d’infirmier délivré par le ministère de la Santé et de la Prévention médicale,pour les diplômés des secteurs public et privé. - En deuxième lieu,il y a la formation continue spécialisée,dans les huit filières suivantes:enseignement et administration,anesthésie et réanimation,kinésithérapie,biologie,imagerie médicale,odontologie,ophtalmologie et néphrologie.Elle est offerte sur une période de deux ans,par l’École nationale de développement sanitaire et social (ENDSS).Le profil de sortie permet aux soignants d’exercer leur profession spécialisée avec le diplôme de technicien supérieur de santé.
more
J. European Academy of Dermatology and Venereology, 4 August 2014
Journal of Pulmonary & Respiratory Medicine 6: 326. doi:10.4172/2161-105X.1000326
A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
AHA/ASA Guideline
DOI: 10.1161/STR.0000000000000158
This article was published on December 10, 2020, and updated on December 16, 2020, at NEJM.org. DOI: 10.1056/NEJMoa2034577
Advocacy report March 2011
303100 03/2011 E 1,000
Over the past few weeks, members of the C4PTF for the Ukraine Response have started mapping the different protection risks that refugees and IDPs are facing in Ukraine and while travelling. This work has been notably built upon efforts conducted in each country, such as the GBV Risk Analysis for CVA... in Ukraine.
more
Patients with diabetes are at increased risk of developing cardiovascular disease (CVD) with its manifestations of coronary artery disease (CAD), heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and peripheral artery diseases. In addition, diabetes is a major risk factor f...or developing chronic kidney disease (CKD), which in itself is associated with developing CVD. The combination of diabetes with these cardio-renal comorbidities enhances the risk not only for cardiovascular (CV) events but also for CV and all-cause mortality. The current European Society of Cardiology (ESC) Guidelines on the management of cardiovascular disease in patients with diabetes are designed to guide prevention and management of the manifestations of CVD in patients with diabetes based on data published until end of January 2023. Over the last decade, the results of various large cardiovascular outcome trials (CVOTs) in patients with diabetes at high CV risk with novel glucose- lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), such as finerenone have substantially expanded available therapeutic op-
tions, leading to numerous evidence-based recommendations for the management of this patient population.
more
sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ...optimal care. The South African Thoracic Society (SATS) first published a guideline for the management of chronic persistent asthma in 1992, which has subsequently been revised several times.
The main aim of the present document was to revise and update SATS’ statement on the suggested management of chronic asthma, based on the need to promote optimal care and control of asthma, together with the incorporation of new concepts and drug developments. This revised document reinforces optimal care and incorporates the following primary objectives to achieve the recent advances in asthma care:
• continued emphasis on the use of inhaled corticosteroids (ICS) as the foundation of asthma treatment
• to reduce the reliance on short-acting beta-2 agonist (SABA) monotherapy for asthma symptoms
• to incorporate the evidence and strategy for the use of the combination of an ICS and formoterol for acute symptom relief (instead of a SABA)
• to incorporate the evidence and strategy for the use of as-needed ICS-long-acting beta agonists (LABA) for patients with infrequent symptoms or ‘mild’ asthma
• to incorporate the evidence and strategy for the use of a long-acting muscarinic antagonist (LAMA) in combination with ICS-LABA; and
• to incorporate the evidence and strategy for the use of and management with a biologic therapy in severe asthma.
more
Document No. : FDA/SMC/CTD/GL-CCT/2013/01
Voices from Eastern Aleppo. A Compilation of Testimonies Illustrating the Hardships of Daily Life in Eastern Aleppo under Barrel Bombings, through the Eyes of Local Residents